PODD
What one share of Insulet holds
Surgical and Medical Instruments and Apparatus
Insulet Corporation (“we” or the “Company”) is primarily engaged in the development, manufacture, and sale of its proprietary continuous insulin delivery systems for people with insulin-dependent diabetes. The Omnipod platform includes: the Omnipod® 5 Automated Insulin Delivery System (“Omnipod 5”), the Omnipod DASH® Insulin Management System (“Omnipod DASH”), and the Omnipod Insulin Management System (“Classic Omnipod”).
Insulet’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $42.72 |
|---|---|
| Profit | $5.25 |
| Capex (buildings and equipment) | $3.04 |
| Free cash flow | $4.11 |
| Cash and investments | $7.71 |
| Debt | $13.67 |
| Book value | $20.51 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $6.41 | −$0.48 | $0.39 | −$0.11 | — | $1.10 |
| 2017 | $8.00 | −$0.46 | $1.27 | −$0.56 | — | $2.72 |
| 2018 | $9.24 | $0.05 | $2.58 | −$1.99 | — | $3.58 |
| 2019 | $11.85 | $0.19 | $2.63 | −$1.05 | — | $1.21 |
| 2020 | $13.71 | $0.10 | $1.96 | −$0.68 | — | $9.14 |
| 2021 | $16.02 | $0.24 | $1.63 | −$2.62 | — | $8.04 |
| 2022 | $18.67 | $0.07 | $1.76 | −$0.06 | — | $6.85 |
| 2023 | $23.05 | $2.94 | $1.03 | $0.95 | — | $10.48 |
| 2024 | $28.04 | $5.78 | $1.69 | $4.13 | — | $17.26 |
| 2025 | $37.67 | $3.48 | $2.67 | $5.25 | — | $21.53 |